139 related articles for article (PubMed ID: 38222349)
1. Predicting premature discontinuation of medication for opioid use disorder from electronic medical records.
Lopez I; Fouladvand S; Kollins S; Chen CA; Bertz J; Hernandez-Boussard T; Lembke A; Humphreys K; Miner AS; Chen JH
AMIA Annu Symp Proc; 2023; 2023():1067-1076. PubMed ID: 38222349
[TBL] [Abstract][Full Text] [Related]
2. Predictability of buprenorphine-naloxone treatment retention: A multi-site analysis combining electronic health records and machine learning.
Nateghi Haredasht F; Fouladvand S; Tate S; Chan MM; Yeow JJL; Griffiths K; Lopez I; Bertz JW; Miner AS; Hernandez-Boussard T; Chen CA; Deng H; Humphreys K; Lembke A; Vance LA; Chen JH
Addiction; 2024 Jun; ():. PubMed ID: 38923168
[TBL] [Abstract][Full Text] [Related]
3. Examining differences in retention on medication for opioid use disorder: An analysis of Ohio Medicaid data.
Zhang P; Tossone K; Ashmead R; Bickert T; Bailey E; Doogan NJ; Mack A; Schmidt S; Bonny AE
J Subst Abuse Treat; 2022 May; 136():108686. PubMed ID: 34953637
[TBL] [Abstract][Full Text] [Related]
4. Prior National Drug Abuse Treatment Clinical Trials Network (CTN) opioid use disorder trials as background and rationale for NIDA CTN-0100 "optimizing retention, duration and discontinuation strategies for opioid use disorder pharmacotherapy (RDD)".
Shulman M; Weiss R; Rotrosen J; Novo P; Costello E; Nunes EV
Addict Sci Clin Pract; 2021 Mar; 16(1):15. PubMed ID: 33676577
[TBL] [Abstract][Full Text] [Related]
5. The impact of psychiatric comorbidity on treatment discontinuation among individuals receiving medications for opioid use disorder.
Friesen EL; Kurdyak P
Drug Alcohol Depend; 2020 Nov; 216():108244. PubMed ID: 32861134
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of an emergency department-based opioid overdose survivor intervention: Difference-in-difference analysis of electronic health record data to assess key outcomes.
Watson DP; Weathers T; McGuire A; Cohen A; Huynh P; Bowes C; O'Donnell D; Brucker K; Gupta S
Drug Alcohol Depend; 2021 Apr; 221():108595. PubMed ID: 33610095
[TBL] [Abstract][Full Text] [Related]
7. Factors associated with retention on medications for opioid use disorder among a cohort of adults seeking treatment in the community.
Biondi BE; Vander Wyk B; Schlossberg EF; Shaw A; Springer SA
Addict Sci Clin Pract; 2022 Mar; 17(1):15. PubMed ID: 35255967
[TBL] [Abstract][Full Text] [Related]
8. Retention With Medication for Opioid Use Disorder: The Role of the Primary Care Relationship.
Munger J; Back E
J Addict Med; 2022 Sep-Oct 01; 16(5):577-580. PubMed ID: 35020699
[TBL] [Abstract][Full Text] [Related]
9. Drug use patterns and factors related to the use and discontinuation of medications for opioid use disorder in the age of fentanyl: findings from a mixed-methods study of people who use drugs.
Hughto JMW; Tapper A; Rapisarda SS; Stopka TJ; Palacios WR; Case P; Silcox J; Moyo P; Green TC
Subst Abuse Treat Prev Policy; 2023 May; 18(1):30. PubMed ID: 37217975
[TBL] [Abstract][Full Text] [Related]
10. Injectable naltrexone, oral naltrexone, and buprenorphine utilization and discontinuation among individuals treated for opioid use disorder in a United States commercially insured population.
Morgan JR; Schackman BR; Leff JA; Linas BP; Walley AY
J Subst Abuse Treat; 2018 Feb; 85():90-96. PubMed ID: 28733097
[TBL] [Abstract][Full Text] [Related]
11. Availability of Medications for the Treatment of Opioid Use Disorder Among Pregnant and Postpartum Individuals in US Jails.
Sufrin C; Kramer CT; Terplan M; Fiscella K; Olson S; Voegtline K; Latkin C
JAMA Netw Open; 2022 Jan; 5(1):e2144369. PubMed ID: 35050354
[TBL] [Abstract][Full Text] [Related]
12. Using Machine Learning to Predict Treatment Adherence in Patients on Medication for Opioid Use Disorder.
Burgess-Hull AJ; Brooks C; Epstein DH; Gandhi D; Oviedo E
J Addict Med; 2023 Jan-Feb 01; 17(1):28-34. PubMed ID: 35914118
[TBL] [Abstract][Full Text] [Related]
13. Characterizing initiation, use, and discontinuation of extended-release buprenorphine in a nationally representative United States commercially insured cohort.
Morgan JR; Walley AY; Murphy SM; Chatterjee A; Hadland SE; Barocas J; Linas BP; Assoumou SA
Drug Alcohol Depend; 2021 Aug; 225():108764. PubMed ID: 34051547
[TBL] [Abstract][Full Text] [Related]
14. Using machine learning to study the effect of medication adherence in Opioid Use Disorder.
Warren D; Marashi A; Siddiqui A; Eijaz AA; Pradhan P; Lim D; Call G; Dras M
PLoS One; 2022; 17(12):e0278988. PubMed ID: 36520864
[TBL] [Abstract][Full Text] [Related]
15. Initiation and Treatment Discontinuation of Medications for Opioid Use Disorder in Pregnant People Compared With Nonpregnant People.
Xu KY; Jones HE; Schiff DM; Martin CE; Kelly JC; Carter EB; Bierut LJ; Grucza RA
Obstet Gynecol; 2023 Apr; 141(4):845-853. PubMed ID: 36897142
[TBL] [Abstract][Full Text] [Related]
16. Identifying risk of opioid use disorder for patients taking opioid medications with deep learning.
Dong X; Deng J; Rashidian S; Abell-Hart K; Hou W; Rosenthal RN; Saltz M; Saltz JH; Wang F
J Am Med Inform Assoc; 2021 Jul; 28(8):1683-1693. PubMed ID: 33930132
[TBL] [Abstract][Full Text] [Related]
17. Impact of fentanyl use on initiation and discontinuation of methadone and buprenorphine/naloxone among people with prescription-type opioid use disorder: secondary analysis of a Canadian treatment trial.
Socias ME; Wood E; Le Foll B; Lim R; Choi JC; Mok WY; Bruneau J; Rehm J; Wild TC; Bozinoff N; Hassan A; Jutras-Aswad D;
Addiction; 2022 Oct; 117(10):2662-2672. PubMed ID: 35712892
[TBL] [Abstract][Full Text] [Related]
18. Development and validation of machine-learning algorithms predicting retention, overdoses, and all-cause mortality among US military veterans treated with buprenorphine for opioid use disorder.
J Hayes C; Bin Noor N; Raciborski RA; C Martin B; J Gordon A; J Hoggatt K; Hudson T; A Cucciare M
J Addict Dis; 2024 Jun; ():1-18. PubMed ID: 38946144
[TBL] [Abstract][Full Text] [Related]
19. Drug court utilization of medications for opioid use disorder in high opioid mortality communities.
Marlowe DB; Theiss DS; Ostlie EM; Carnevale J
J Subst Abuse Treat; 2022 Oct; 141():108850. PubMed ID: 35931014
[TBL] [Abstract][Full Text] [Related]
20. Implementation and evaluation of Missouri's Medication First treatment approach for opioid use disorder in publicly-funded substance use treatment programs.
Winograd RP; Wood CA; Stringfellow EJ; Presnall N; Duello A; Horn P; Rudder T
J Subst Abuse Treat; 2020 Jan; 108():55-64. PubMed ID: 31277891
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
